secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001655759-24-000113
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q2 2024: $1.2B cash, $150M Novartis upfront, VERITAC-2 data 4Q24/1Q25
-----------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $1.234B as of June 30, 2024; sufficient into 2027.
- Revenue $76.5M (+$22M YoY) driven by $45.4M from Novartis ARV-766 license/asset purchase.
- R&D expenses $93.7M (-$9.7M YoY); G&A $31.3M (+$5.6M) on higher personnel and professional fees.
- VERITAC-2 enrollment on track to complete 4Q24; topline data now expected 4Q24/1Q25.
- Novartis deal closed with $150M upfront; potential $1.01B in milestones plus royalties; leadership strengthened (CFO, President R&D, CSO, CBO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/0001655759-24-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000113/arvn-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer